BizJournals Portfolio

Adapt or Die

What comes after discoveries in biotech? A hard look at bio-economics, politics, personality, and ethics, this week with help from Andy Grove.

Think Disruptive Think Disruptive

Forget about startups, says Intel's co-founder. It's large companies that generate real change. Apple upended the music industry. Wal-Mart may reinvent health care. Now if only G.E. would build an electric car. Read More

Recent Columns

Andy Grove
1 of 2 NEXT

Recently, I had coffee with former Intel chief executive Andy Grove moments after he had admonished a room full of scientists about being too good at what they do.

"They are so caught up in doing the best science that they are failing to translate that science into anything useful," he said, his Hungarian-lilted voice rising and blue eyes intense.

"When we set out to develop the microchip," he had just told a packed room at the Society for Neuroscience annual meeting in San Diego, "we did not try to make the best chip, but one that worked for as little cost as possible." If one chip idea didn't work, he said, they tossed it and built a better one, learning from their mistakes.

Grove, who is 71 and has Parkinson's disease, suggested that bio-scientists should follow the same example. He called for a "cultural revolution" that rewards curiosity, risk-taking, and lessons learned from failure.

Currently, he said, the culture rewards work that pleases reviewers, takes few risks, and retains an Ivory Tower mentality that puts elegant science above finding speedy treatments that work.

During the follow-up question-and-answer session, someone in the audience gave the obvious retort to Grove: That drugs and medical devices are not microchips. They have to work in humans, with no margin for error.

Yet Grove has a point, if for no other reason than that something is seriously amiss when the number of drugs approved by the U.S. Food and Drug Administration each year is going down at the same time the money research and development spending is going up.

Combined spending on R&D at the National Institutes of Health and in the pharmaceutical industry has tripled in 20 years. In 2007, the Food and Drug Administration will approve fewer than 20 new drugs, less than half the number per year just a decade ago.

At the same time, science has produced a raft of pure research discoveries that boggle the mind. From learning how cancer forms to developing a recipe for transforming skin cells into embryonic stem cells capable of growing into any organ or cell in the body.

Comments

If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.

Connect With Portfolio.com

Come on, like us—you know you want to.

Follow us and if you're an innovative entrepreneur, we'll return the favor.

Today's top stories, conversation starters, and the back nine business bites.

spotlight on

Slideshows

500 Startups Hits New York

Dave McClure's brainchild makes its way to New York and introduces East Coast money folks to some intriguing new companies. View Slideshow